Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.
16 Nov, 2021 | 08:14h | UTCLong-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases